The prospects for the French pharmaceutical and biotech sector are looking decidedly rosier than they have done for some time – at least if recent announcements by a joint government/industry body are anything to go by1.
A number of measures are already being put in place to strengthen the country’s manufacturing base, consolidate its position in the biotechnology sector, and increase the use of generics and self-medication...
Please login to read the full article.
